Benitec Biopharma announces public stock offering

Benitec Biopharma Inc. (NASDAQ: BNTC) announced it has commenced an underwritten public offering of its common stock and pre-funded warrants, according to a company statement.

The clinical-stage biotechnology company also plans a concurrent registered direct offering of common stock with long-term investor Suvretta Capital. The offerings are expected to close on November 7, 2025, subject to customary closing conditions.

Benitec intends to grant underwriters a 30-day option to purchase additional shares equal to 15% of the total number of shares and pre-funded warrants sold in the underwritten offering, on the same terms and conditions.

Leerink Partners, TD Cowen and Evercore ISI are serving as bookrunning managers for the proposed offering.

The Securities and Exchange Commission declared effective a registration statement on Form S-3 relating to these securities on September 29, 2025. A prospectus supplement relating to the offerings will be filed with the SEC.

Benitec develops genetic medicines based on its DNA-directed RNA interference platform, which combines RNA interference with gene therapy. The company is advancing therapeutics for conditions including Oculopharyngeal Muscular Dystrophy.

The company cautioned that no assurance can be given that the offerings will be completed on the terms described or at all. The offerings are subject to market and other conditions.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Global Interactive Technologies receives Nasdaq non-compliance notice
• Werewolf Therapeutics to merge with Ambros in $150M private placement